All In Biotech

Drug Trial Radar · NCT06548230

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Mar 5, 2025

Primary completion

Dec 1, 2027

Study completion Dec 1, 2029

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate safety and determine the recommended Phase II dose (RP2D). We hypothesize that targeting leukemia stem/progenitor cells (LSCs) with nadunolimab (IL1RAP antibody) alone or in combination with current therapies of azacitidine (HMA) and venetoclax (Bcl-2 inhibitor), is an effective treatment strategy for high-risk MDS and AML, and with a clinical trial we will establish the safety and the early efficacy of this approach.

Conditions

  • Myelodysplastic Syndrome(MDS)
  • Acute Myelogenous Leukemia (AML)

Interventions

  • NadunolimabDrug

    Give by IV

  • AzacitidineDrug

    Given by IV

  • VenetoclaxDrug

    Given by mouth (PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Adverse EventsTime frame: Through study completion; an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.